The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., ...

Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...

Hypertrophic cardiomyopathy (HCM) is a condition where some of the heart muscle becomes too thick, (a.k.a., hypertrophied, a typical diagnostic criterion is a 15 millimeters or greater left ventricle ...

Hypertrophic cardiomyopathy (HCM) is the most common inherited form of heart disease, associated with over 1,000 mutations, many in β-cardiac myosin (MYH7). Molecular studies of myosin with different ...